Surrogate marker guidelines at hand

Surrogate marker guidelines at hand Coincident to the pending decision by Immunization Products Ltd. on whether to seek accelerated FDA approval of its HIV therapeutic vaccine, the agency is close to completing a year-long review of its guidelines for use of surrogate markers.

The FDA Office of Drug Evaluation is completing the formal guidelines and will release them in several

Read the full 617 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers